Kymera Therapeutics, Inc. (NASDAQ: KYMR)

Sector: Healthcare Industry: Biotechnology CIK: 0001815442
P/B 7.77
P/E -24.91
P/S 168.10
Market Cap 7.35 Bn
ROIC (Qtr) -31.83
Div Yield % 0.00
Rev 1y % (Qtr) -26.12
Total Debt (Qtr) 84.00 Mn
Debt/Equity (Qtr) 0.09

About

Stock Price Chart

Analysis

Pros

  • Healthy cash reserves of 118.74M provide 8.64x coverage of short-term debt 13.74M, demonstrating strong liquidity position and minimal refinancing risk.
  • Strong tangible asset base of 1.10B provides 13.12x coverage of total debt 84M, indicating robust asset backing and low credit risk.
  • Tangible assets of 1.10B provide exceptional 29.60x coverage of deferred revenue 37.24M, showing strong service capability backing.
  • Operating cash flow of (227.93M) fully covers other non-current liabilities (23.28M) by 9.79x, showing strong long-term stability.
  • Long-term investments of 473.06M provide solid 6.73x coverage of long-term debt 70.25M, indicating strategic financial planning.

Cons

  • Investment activities of (58.09M) provide weak support for R&D spending of 304.55M, which is -0.19x, suggesting potentially insufficient investment in innovation relative to other capital deployment.
  • Operating cash flow of (227.93M) provides insufficient coverage of deferred revenue obligations of 37.24M, which is -6.12x, raising concerns about future service delivery capabilities.
  • Short-term investments of 392.73M significantly exceed cash reserves of 118.74M, which is 3.31x, indicating potentially excessive yield-seeking behavior at the expense of liquidity.
  • The company's operating cash flow of (227.93M) shows concerning coverage of stock compensation expenses of 59.25M, with a -3.85 ratio indicating potential earnings quality issues.
  • Free cash flow of (230.21M) provides weak coverage of capital expenditures of 2.28M, with a -101.01 ratio suggesting additional external financing needs for growth initiatives.

Peer Comparison

Companies in the Biotechnology
S.No. Ticker Company Market Cap P/E P/S Total Debt (Qtr)
1 SMMT Summit Therapeutics Inc. 1,349.40 Bn -1,464.17 0.00 0.01 Bn
2 ONC BeOne Medicines Ltd. 437.43 Bn 6,381.20 87.97 1.90 Bn
3 VRTX Vertex Pharmaceuticals Inc / Ma 116.09 Bn 31.59 9.90 1.83 Bn
4 REGN Regeneron Pharmaceuticals, Inc. 78.10 Bn 17.06 5.48 2.71 Bn
5 ALNY Alnylam Pharmaceuticals, Inc. 55.87 Bn 1,282.42 17.40 3.21 Bn
6 ARGX Argenx Se 52.85 Bn 35.08 27,559.65 -
7 BNTC Benitec Biopharma Inc. 41.75 Bn -998.33 0.00 0.00 Bn
8 INSM INSMED Inc 37.80 Bn -31.93 84.56 0.74 Bn

Industry Comparisons

Current Valuation

Metric Value Industry Percentile
EV to Assets 6.44 12.31
EV to Cash from Ops. -31.13 23.25
EV to Debt 84.48 738.44
EV to EBIT -24.07 -9.16
EV to EBITDA -21.90 6.95
EV to Free Cash Flow [EV/FCF] -30.82 21.90
EV to Market Cap 0.97 65.67
EV to Revenue 162.25 227.32
Price to Book Value [P/B] 7.77 22.34
Price to Earnings [P/E] -24.91 -11.77

Dividend Metrics

Metric Value Industry Percentile
Dividend Coverage Ratio 0.00 -11.94
Dividend Payout Ratio % 0.00 0.16
Dividend per Basic Share 0.00 0.01
FCF Dividend Payout Ratio % 0.00 -0.14
Interest Coverage -874.73 841.00

Growth Metrics

Metric Value Industry Percentile
Capex Growth (1y) % 90.31 -27.13
Cash and Equivalents Growth (1y) % 1.92 734.65
Dividend Growth (1y) % 0.00 0.01
EBIAT Growth (1y) % -76.27 -46.93
EBITDA Growth (1y) % -67.08 -1.68
EBIT Growth (1y) % -76.27 -56.45
EBT Growth (1y) % -76.22 -12.70
EPS Growth (1y) % -53.85 -28.31
FCF Growth (1y) % -55.34 -31.90
Gross Profit Growth (1y) % -50.05 226.84

Liquidity Ratios

Metric Value Industry Percentile
Asset Utilization Ratio 0.04 0.14
Cash Payout Ratio 0.00 0.00
Cash Ratio 1.66 3.85
Current Ratio 7.38 7.27
Debt to Equity Ratio 0.09 0.40
Interest Cover Ratio -874.73 841.00
Times Interest Earned -874.73 841.00

Profitability

Metric Value Industry Percentile
EBITDA Margin % -655.10 -18,234.31
EBIT Margin % -674.04 -18,580.80
EBT Margin % -674.81 -19,488.74
Gross Margin % 100.00 -7.59
Net Profit Margin % -674.80 -19,439.22